The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.
Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.
The FDA has yet to determine if fecal microbiome transplants should be treated like a drug or like a blood transfusion, the New York Times reports.
Signature Science will assess the validity of metagenomic and metatranscriptomic analyses to detect the transmission of viable pathogens in healthcare settings.
Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.
Researchers in the US and Europe are implementing pathogen sequencing surveillance programs to track infectious diseases within hospitals.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.
The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.